在 iTIND 手术前使用 Schelin 导管进行经尿道前列腺内麻醉 (TUIA)

IF 5.1 2区医学 Q1 ONCOLOGY

Prostate Cancer and Prostatic Diseases Pub Date : 2024-09-10 DOI:10.1038/s41391-024-00892-2

Silvia Secco, Alberto Olivero, Mattia Longoni, Paolo Dell’Oglio, Stefano Tappero, Edoardo Dibilio, Tommaso Saccucci, Giampaolo Siena, Aldo Massimo Bocciardi, Antonio Galfano, Luca Cindolo

{"title":"在 iTIND 手术前使用 Schelin 导管进行经尿道前列腺内麻醉 (TUIA)","authors":"Silvia Secco, Alberto Olivero, Mattia Longoni, Paolo Dell’Oglio, Stefano Tappero, Edoardo Dibilio, Tommaso Saccucci, Giampaolo Siena, Aldo Massimo Bocciardi, Antonio Galfano, Luca Cindolo","doi":"10.1038/s41391-024-00892-2","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background/Objectives</h3><p>Endorsing the principles of minimal invasiveness in benign-prostatic hyperplasia (BPH) surgery, we conducted the first evaluation of transurethral intraprostatic anesthesia (TUIA) using Schelin catheter® (SC) prior to iTIND positioning.</p><h3 data-test=\"abstract-sub-heading\">Subjects/Methods</h3><p>Of 23 patients enrolled, 11 (48%) received TUIA via SC whereas the remaining underwent standard anesthesia protocol. Pain was assessed using visual analogue scale (VAS).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>No differences between cohorts were observed for pain during the device implantation and removal. Conversely, significantly lower median VAS scores were reported at 24- (1.0 vs. 3.0) and 48- (1.0 vs. 2.5) hour follow-up favoring TUIA.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>SC TUIA offers effective pain control during iTIND procedures, supporting its use in outpatient settings.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"408 1","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure\",\"authors\":\"Silvia Secco, Alberto Olivero, Mattia Longoni, Paolo Dell’Oglio, Stefano Tappero, Edoardo Dibilio, Tommaso Saccucci, Giampaolo Siena, Aldo Massimo Bocciardi, Antonio Galfano, Luca Cindolo\",\"doi\":\"10.1038/s41391-024-00892-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background/Objectives</h3><p>Endorsing the principles of minimal invasiveness in benign-prostatic hyperplasia (BPH) surgery, we conducted the first evaluation of transurethral intraprostatic anesthesia (TUIA) using Schelin catheter® (SC) prior to iTIND positioning.</p><h3 data-test=\\\"abstract-sub-heading\\\">Subjects/Methods</h3><p>Of 23 patients enrolled, 11 (48%) received TUIA via SC whereas the remaining underwent standard anesthesia protocol. Pain was assessed using visual analogue scale (VAS).</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>No differences between cohorts were observed for pain during the device implantation and removal. Conversely, significantly lower median VAS scores were reported at 24- (1.0 vs. 3.0) and 48- (1.0 vs. 2.5) hour follow-up favoring TUIA.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>SC TUIA offers effective pain control during iTIND procedures, supporting its use in outpatient settings.</p>\",\"PeriodicalId\":20727,\"journal\":{\"name\":\"Prostate Cancer and Prostatic Diseases\",\"volume\":\"408 1\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate Cancer and Prostatic Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41391-024-00892-2\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-024-00892-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的为了支持良性前列腺增生症（BPH）手术的微创原则，我们首次评估了在 iTIND 定位前使用 Schelin 导管® (SC) 进行经尿道前列腺内麻醉（TUIA）的情况。在 23 例入组患者中，11 例（48%）通过 SC 接受了 TUIA，其余患者则接受了标准麻醉方案。采用视觉模拟量表（VAS）对疼痛进行评估。结果在设备植入和移除过程中，未观察到不同组别之间的疼痛差异。相反，在 24 小时（1.0 对 3.0）和 48 小时（1.0 对 2.5）的随访中，VAS 评分中位数明显低于 TUIA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure

查看原文本刊更多论文

Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure

Background/Objectives

Endorsing the principles of minimal invasiveness in benign-prostatic hyperplasia (BPH) surgery, we conducted the first evaluation of transurethral intraprostatic anesthesia (TUIA) using Schelin catheter® (SC) prior to iTIND positioning.

Subjects/Methods

Of 23 patients enrolled, 11 (48%) received TUIA via SC whereas the remaining underwent standard anesthesia protocol. Pain was assessed using visual analogue scale (VAS).

Results

No differences between cohorts were observed for pain during the device implantation and removal. Conversely, significantly lower median VAS scores were reported at 24- (1.0 vs. 3.0) and 48- (1.0 vs. 2.5) hour follow-up favoring TUIA.

Conclusions

SC TUIA offers effective pain control during iTIND procedures, supporting its use in outpatient settings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学

CiteScore

10.00

自引率

6.20%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.